Now Playing

Cancer drug Taxotere linked to permanent hair loss

posted on:
April 6, 2017

category:
Pharmaceutical

Beasley Allen lawyer Beau Darley joins Beasley Allen Report host and Beasley Allen lawyer Gibson Vance to discuss how an expected, temporary side effect of chemotherapy could prove permanent for patients taking Taxotere, a cancer treatment drug available since 1996. Beau explains Taxotere’s manufacturer, Sanofi-Aventis, failed to inform the FDA, health care providers and the public of the permanent hair loss risk until the FDA forced the company to include a warning on the drug in 2015. The two also discuss how defective medical devices and drugs make it onto the consumer market.

Courtesy of: Beasley Allen Report

back to top